11.3. The Advisory Committee recommended that avalglucosidase alfa for the treatment of late onset Pompe disease be funded with a medium priority.

Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year Galafold®Q3 Revenue of $120.4M, up 20% Year-over-Year PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: ...